P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 20.93 CNY -0.05% Market Closed
Market Cap: 15.3B CNY
Have any thoughts about
Pacific Shuanglin Bio pharmacy Co Ltd?
Write Note

Pacific Shuanglin Bio pharmacy Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pacific Shuanglin Bio pharmacy Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
P
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Gross Profit
ÂĄ1.4B
CAGR 3-Years
21%
CAGR 5-Years
26%
CAGR 10-Years
20%
Beigene Ltd
HKEX:6160
Gross Profit
ÂĄ14.7B
CAGR 3-Years
108%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Gross Profit
ÂĄ6.1B
CAGR 3-Years
12%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Gross Profit
ÂĄ4.5B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Gross Profit
ÂĄ9.2B
CAGR 3-Years
-11%
CAGR 5-Years
18%
CAGR 10-Years
34%
Imeik Technology Development Co Ltd
SZSE:300896
Gross Profit
ÂĄ2.7B
CAGR 3-Years
61%
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
15.3B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Intrinsic Value
33.41 CNY
Undervaluation 37%
Intrinsic Value
Price
P

See Also

What is Pacific Shuanglin Bio pharmacy Co Ltd's Gross Profit?
Gross Profit
1.4B CNY

Based on the financial report for Sep 30, 2024, Pacific Shuanglin Bio pharmacy Co Ltd's Gross Profit amounts to 1.4B CNY.

What is Pacific Shuanglin Bio pharmacy Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
20%

Over the last year, the Gross Profit growth was 49%. The average annual Gross Profit growth rates for Pacific Shuanglin Bio pharmacy Co Ltd have been 21% over the past three years , 26% over the past five years , and 20% over the past ten years .

Back to Top